Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
-
REGULATORY MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
-
REGULATORY MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
-
REGULATORY Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
-
BUSINESS Kidswell Is Open to M&As Amid Challenging Financing Environment: CEO
September 4, 2024
-
BUSINESS BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
-
BUSINESS Takeda Pushes Back Shipping Date as Trucker Overtime Cap Hits Logistics
September 2, 2024
-
BUSINESS AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
-
REGULATORY MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
-
REGULATORY Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
-
BUSINESS Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
-
REGULATORY High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
-
ACADEMIA A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
-
BUSINESS A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
-
REGULATORY MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
August 26, 2024
-
BUSINESS Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
-
BUSINESS A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
-
COMMENTARY Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
BUSINESS Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
-
REGULATORY Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…